[go: up one dir, main page]

HUE036663T2 - Készítmény anti-alfa4béta7 antitesthez - Google Patents

Készítmény anti-alfa4béta7 antitesthez

Info

Publication number
HUE036663T2
HUE036663T2 HUE12721093A HUE12721093A HUE036663T2 HU E036663 T2 HUE036663 T2 HU E036663T2 HU E12721093 A HUE12721093 A HU E12721093A HU E12721093 A HUE12721093 A HU E12721093A HU E036663 T2 HUE036663 T2 HU E036663T2
Authority
HU
Hungary
Prior art keywords
antibody
preparation
Prior art date
Application number
HUE12721093A
Other languages
English (en)
Inventor
Willow Diluzio
Nobel T Truong
Csanad M Varga
Vaithianathan Palaniappan
Jason Brown
Irving H Fox
Catherine Scholz
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036663(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HUE036663T2 publication Critical patent/HUE036663T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE12721093A 2011-05-02 2012-05-02 Készítmény anti-alfa4béta7 antitesthez HUE036663T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481533P 2011-05-02 2011-05-02
US201161550545P 2011-10-24 2011-10-24
US201261585859P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
HUE036663T2 true HUE036663T2 (hu) 2018-07-30

Family

ID=46085207

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12721093A HUE036663T2 (hu) 2011-05-02 2012-05-02 Készítmény anti-alfa4béta7 antitesthez

Country Status (41)

Country Link
US (14) US20120282249A1 (hu)
EP (4) EP3329965A3 (hu)
JP (7) JP6190360B2 (hu)
KR (7) KR20140145953A (hu)
CN (4) CN108187042A (hu)
AR (1) AR086237A1 (hu)
AU (6) AU2012250873B2 (hu)
BR (1) BR112013028424A2 (hu)
CA (2) CA2834867C (hu)
CL (2) CL2013003146A1 (hu)
CO (1) CO6801647A2 (hu)
CR (1) CR20130677A (hu)
CY (1) CY1119435T1 (hu)
DK (1) DK2704798T3 (hu)
DO (1) DOP2013000253A (hu)
EA (1) EA032729B1 (hu)
EC (2) ECSP13013050A (hu)
ES (1) ES2645187T3 (hu)
GE (1) GEP201706734B (hu)
HK (2) HK1249466A1 (hu)
HR (1) HRP20171432T1 (hu)
HU (1) HUE036663T2 (hu)
IL (5) IL275038B2 (hu)
LT (1) LT2704798T (hu)
MA (1) MA35136B1 (hu)
ME (1) ME02859B (hu)
MX (3) MX348814B (hu)
MY (2) MY172735A (hu)
PE (2) PE20190405A1 (hu)
PH (3) PH12013502236A1 (hu)
PL (1) PL2704798T3 (hu)
PT (1) PT2704798T (hu)
RS (1) RS56397B1 (hu)
SG (1) SG194652A1 (hu)
SI (1) SI2704798T1 (hu)
SM (1) SMT201700508T1 (hu)
TW (3) TWI664980B (hu)
UA (2) UA116189C2 (hu)
UY (1) UY34053A (hu)
WO (1) WO2012151248A2 (hu)
ZA (3) ZA201308069B (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG190679A1 (en) 2010-10-01 2013-07-31 Jason Schrum Engineered nucleic acids and methods of use thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TWI698254B (zh) 2011-05-02 2020-07-11 美商千禧製藥公司 抗-α4β7抗體之調配物
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2707251C2 (ru) 2011-10-03 2019-11-25 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
CN105163763B (zh) * 2013-03-15 2019-07-02 艾伯维德国有限责任两合公司 抗egfr抗体药物偶联物制剂
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
CN106456784A (zh) * 2014-04-16 2017-02-22 拜康有限公司 包含摩尔过量的山梨醇的稳定蛋白质制剂
US10532051B2 (en) * 2014-10-06 2020-01-14 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
EP3581585A1 (en) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CN113893341A (zh) * 2015-08-11 2022-01-07 国立大学法人大阪大学 抗体
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
EP3430053A1 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
IL261750B2 (en) * 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease
WO2017158393A1 (en) * 2016-03-18 2017-09-21 Oslo University Hospital Hf Methods of treating graft-versus-host disease
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
MA45245A (fr) * 2016-06-12 2019-04-17 Millennium Pharm Inc Méthode de traitement de maladie intestinale inflammatoire
CN118873480A (zh) * 2016-10-07 2024-11-01 瑞泽恩制药公司 室温稳定的冻干蛋白质
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
HUE058664T2 (hu) * 2016-12-23 2022-09-28 Immunogen Inc ADAM9-et célzó immunkonjugátumok és eljárások azok felhasználására
BR112019022268A2 (pt) * 2017-04-28 2020-05-19 Millennium Pharm Inc método para o tratamento de distúrbios pediátricos
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
KR20200011457A (ko) * 2017-05-26 2020-02-03 밀레니엄 파머슈티컬스 인코퍼레이티드 만성 맹낭염의 치료 방법
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
TWI648098B (zh) 2017-11-14 2019-01-21 亞智科技股份有限公司 氣液混合機構、製程設備及氣液混合方法
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
JP2021521171A (ja) * 2018-04-10 2021-08-26 ドクター レディズ ラボラトリーズ リミテッド 治療用抗体の安定な製剤
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
CN112218654A (zh) * 2018-04-10 2021-01-12 雷迪博士实验室有限公司 抗体制剂
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
CN109239335A (zh) * 2018-09-11 2019-01-18 广州万孚生物技术股份有限公司 联检试纸条及其制备方法
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer
PH12021551916A1 (en) 2019-02-18 2022-05-23 Lilly Co Eli Therapeutic antibody formulation.
CN117925711A (zh) * 2019-06-10 2024-04-26 武田药品工业株式会社 用于抗体生产的细胞培养方法和组合物
MA56129A (fr) 2019-06-10 2022-04-13 Takeda Pharmaceuticals Co Procédés de production d'un anticorps anti-alpha4béta7
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
EP4106727A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmaceutical formulations
CN113577281A (zh) * 2020-04-30 2021-11-02 中国科学院分子细胞科学卓越创新中心 调控整合素β亚基的试剂和方法
AR122983A1 (es) 2020-07-16 2022-10-19 Abbvie Inc ANTICUERPOS ANTI-a4b7
US20240100158A1 (en) * 2021-01-20 2024-03-28 Dr. Reddy’S Laboratories Limited Freeze dried antibody formulations and methods thereof
US20240239900A1 (en) * 2021-05-07 2024-07-18 Dr. Reddy’S Laboratories Limited A method of improving stability of an antibody formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US774216A (en) 1903-11-19 1904-11-08 Alexander F Ward Machine for pointing and lapping hoops.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3852236T2 (de) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
JPH04504501A (ja) 1988-12-23 1992-08-13 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ホーミング配列およびそれらの使用
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU674302B2 (en) 1992-02-12 1996-12-19 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
NZ262615A (en) 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CN1211123C (zh) 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla－4的人源化抗体
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
ES2290955T3 (es) 1995-02-10 2008-02-16 Millennium Pharmaceuticals, Inc. Adresinas vasculares de mucosas y sus usos.
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
AU2003213231A1 (en) 2002-02-25 2003-09-09 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
MXPA04011465A (es) 2002-05-24 2005-02-14 Millennium Pharm Inc Inhibidores de ccr9 y metodos de uso de los mismos.
KR100874292B1 (ko) 2002-11-18 2008-12-18 케모센트릭스 아릴 술폰아마이드
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
PL2990422T3 (pl) * 2004-09-03 2018-11-30 Genentech, Inc. Humanizowani antagoniści anty-beta7 i ich zastosowania
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
PE20081179A1 (es) 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
WO2008140602A2 (en) 2006-12-07 2008-11-20 The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN
JP2010512356A (ja) 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
EA034783B1 (ru) 2009-03-20 2020-03-20 Эмджен Инк. Антитело-антагонист, специфичное для гетеродимера альфа4бета7
AU2010263058A1 (en) * 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
EP3412309A1 (en) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Methods of administering beta7 integrin antagonists
TWI698254B (zh) 2011-05-02 2020-07-11 美商千禧製藥公司 抗-α4β7抗體之調配物
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3581585A1 (en) * 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease

Also Published As

Publication number Publication date
IL296847A (en) 2022-11-01
UY34053A (es) 2012-11-30
HK1256106A1 (zh) 2019-09-13
TWI664980B (zh) 2019-07-11
KR20140145953A (ko) 2014-12-24
MX356827B (es) 2018-06-15
TWI664978B (zh) 2019-07-11
IL275038A (en) 2020-07-30
SG194652A1 (en) 2013-12-30
TW201718012A (zh) 2017-06-01
CN108079291A (zh) 2018-05-29
KR101923378B1 (ko) 2018-11-29
KR20220154834A (ko) 2022-11-22
EP4378484A2 (en) 2024-06-05
JP7492057B2 (ja) 2024-05-28
CA3028209A1 (en) 2012-11-08
US10143752B2 (en) 2018-12-04
CL2017000830A1 (es) 2017-12-22
US20120282249A1 (en) 2012-11-08
JP6473845B2 (ja) 2019-02-20
PE20190405A1 (es) 2019-03-14
US12171832B2 (en) 2024-12-24
ZA201707158B (en) 2019-01-30
CY1119435T1 (el) 2018-03-07
KR101923371B1 (ko) 2018-11-29
TW201906631A (zh) 2019-02-16
CL2013003146A1 (es) 2014-07-25
KR102465394B1 (ko) 2022-11-09
EP3263178A1 (en) 2018-01-03
JP2023076616A (ja) 2023-06-01
IL296838A (en) 2022-11-01
PH12018500030A1 (en) 2018-10-15
CO6801647A2 (es) 2013-11-29
JP6534415B2 (ja) 2019-06-26
EP3329965A3 (en) 2018-12-12
MX2021006723A (es) 2022-05-03
ECSP22034515A (es) 2022-05-31
CN108129565A (zh) 2018-06-08
AU2022231726A1 (en) 2022-10-06
US20160340432A1 (en) 2016-11-24
KR102275603B1 (ko) 2021-07-08
US20190076532A1 (en) 2019-03-14
PH12018500030B1 (en) 2022-05-04
AU2019201926A1 (en) 2019-04-11
CN108187042A (zh) 2018-06-22
US9663579B2 (en) 2017-05-30
AU2016231469A1 (en) 2016-10-06
EP4378484A3 (en) 2024-09-04
US20180289811A1 (en) 2018-10-11
AR086237A1 (es) 2013-11-27
US20170002078A1 (en) 2017-01-05
BR112013028424A2 (pt) 2021-05-04
AU2016231469B2 (en) 2018-12-20
UA126545C2 (uk) 2022-11-02
DOP2013000253A (es) 2013-12-31
MX2013012724A (es) 2013-12-06
ZA201806946B (en) 2022-03-30
RS56397B1 (sr) 2017-12-29
WO2012151248A2 (en) 2012-11-08
EP3329965A1 (en) 2018-06-06
AU2012250873A1 (en) 2013-05-09
US20160340431A1 (en) 2016-11-24
GEP201706734B (en) 2017-09-25
ECSP13013050A (es) 2014-01-31
EP2704798A2 (en) 2014-03-12
PL2704798T3 (pl) 2017-12-29
MY183471A (en) 2021-02-19
CA2834867C (en) 2019-02-12
US20210052733A1 (en) 2021-02-25
NZ617833A (en) 2016-04-29
CN103608071B (zh) 2017-12-26
PT2704798T (pt) 2017-11-14
KR20180127540A (ko) 2018-11-28
US20180207279A1 (en) 2018-07-26
MA35136B1 (fr) 2014-05-02
KR20170116217A (ko) 2017-10-18
US20220370617A1 (en) 2022-11-24
IL275038B2 (en) 2023-03-01
ZA201308069B (en) 2016-01-27
AU2020250249B2 (en) 2022-10-06
IL229104A0 (en) 2013-12-31
AU2012250873B2 (en) 2016-07-07
SI2704798T1 (sl) 2017-12-29
EA201391614A1 (ru) 2014-07-30
JP2019108400A (ja) 2019-07-04
PE20141175A1 (es) 2014-09-25
HRP20171432T1 (hr) 2017-11-03
WO2012151248A3 (en) 2013-02-28
ME02859B (me) 2018-04-20
PH12020500336A1 (en) 2021-02-22
UA116189C2 (uk) 2018-02-26
US20250000981A1 (en) 2025-01-02
PH12013502236A1 (en) 2014-01-06
KR102096484B1 (ko) 2020-04-02
US12053526B2 (en) 2024-08-06
KR20180050435A (ko) 2018-05-14
AU2022231726B2 (en) 2025-01-09
JP2018150388A (ja) 2018-09-27
JP6190360B2 (ja) 2017-08-30
JP2021113223A (ja) 2021-08-05
KR20210084711A (ko) 2021-07-07
CA3028209C (en) 2021-01-05
EP2704798B1 (en) 2017-07-12
JP2014514346A (ja) 2014-06-19
IL267668B (en) 2020-10-29
JP6878489B2 (ja) 2021-05-26
CR20130677A (es) 2014-10-07
JP7258941B2 (ja) 2023-04-17
AU2018278866A1 (en) 2019-01-03
SMT201700508T1 (it) 2017-11-15
ES2645187T3 (es) 2017-12-04
IL267668A (en) 2019-08-29
LT2704798T (lt) 2017-10-25
CN108129565B (zh) 2022-09-20
CN103608071A (zh) 2014-02-26
KR20200035503A (ko) 2020-04-03
CN108079291B (zh) 2022-04-08
US10004808B2 (en) 2018-06-26
IL275038B (en) 2022-11-01
US20190231878A1 (en) 2019-08-01
EA032729B1 (ru) 2019-07-31
MY172735A (en) 2019-12-11
MX348814B (es) 2017-06-30
US20200206353A1 (en) 2020-07-02
HK1249466A1 (zh) 2018-11-02
JP2024098027A (ja) 2024-07-19
TWI556828B (zh) 2016-11-11
US9764033B2 (en) 2017-09-19
DK2704798T3 (en) 2017-10-23
AU2018278866B2 (en) 2020-07-09
JP2017137351A (ja) 2017-08-10
US20250041424A1 (en) 2025-02-06
AU2020250249A1 (en) 2020-11-05
CA2834867A1 (en) 2012-11-08
TW201247223A (en) 2012-12-01
US20140377251A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
CY2024011I2 (el) Αντισωματα anti-fcrn
HK1253911A1 (zh) 抗α4β7抗體的製劑
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
HUE036663T2 (hu) Készítmény anti-alfa4béta7 antitesthez
IL259826A (en) Anti-alphabetatisiar antibody
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
DK3275892T3 (da) Præfusions-rsv-f-antigener
DK3653645T3 (da) Monoklonal interleukin-31-antistof
DK2934584T3 (da) Anti-gdf15-antistoffer
CO6801637A2 (es) Formulaciones de anticuerpos
DK2828292T3 (da) Jcv-neutraliserende antistoffer
HRP20181667T1 (hr) Pripravak
DK2935330T3 (da) Anti-notch3-antistoffer
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
CO6841994A2 (es) Anticuerpos
IL231660A0 (en) Composition
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
DOP2011000313A (es) Anticuerpos especificos para caderin-17